Melanotan II vs PT-141

Published August 2026 · Patriot Labs Research Team · ~12 min read

The short version

Melanotan II and PT-141 — the latter also called bremelanotide — are both synthetic melanocortin receptor agonists. Both are cyclic peptides built on the same seven-residue scaffold. Both trace back to α-MSH, a natural signalling peptide carved out of a larger precursor protein. And they differ from each other by a single functional group at one end of the molecule.

That is the unusual thing about this pair. Most peptide comparisons put two unrelated molecules side by side and ask what they have in common. Here the question runs the other way: two molecules that are almost the same, and the work is in explaining why roughly one atom's worth of chemistry produces a measurably different receptor profile.

If you have read our PT-141 explainer, this is the deeper companion piece — the same compound approached through the receptor family rather than through the compound itself. If peptide nomenclature is new, the peptides primer covers the vocabulary used below.

One gene, many messengers: POMC

Neither peptide makes sense without proopiomelanocortin, usually shortened to POMC — a textbook example of one gene producing not one signalling molecule but a whole family of them.

The POMC gene encodes a single long precursor protein, which is then cut proteolytically, at specific basic-residue sites, by enzymes called prohormone convertases. The fragments that fall out are themselves biologically active peptides. The IUPHAR/BPS Guide to PHARMACOLOGY describes POMC as "the precursor of 11 peptides (Pro-ACTH, β-LPH, N-POMC, JP, ACTH, α-MSH, β-MSH, γ-MSH, CLIP, γ-LPH, and β-Endorphin)".¹ One transcript; eleven products; several entirely different signalling systems served from the same starting material.

Which fragments you get depends on which convertase is present, and that varies by tissue. Wang and colleagues put it this way: "PC1 cleaves POMC to produce ACTH and other peptides in the anterior pituitary gland, whereas in lower vertebrates and during fetal and infantile periods in humans, PC2 located in the pars intermedia accounts for the production of MSHs and β-endorphin."² Same precursor, different cells, different output — tissue-specific post-translational control, and a more elegant piece of engineering than "one gene, one hormone".

POMC expression is not confined to the pituitary either — the same review notes POMC mRNA in the hypothalamic arcuate nucleus, the caudal brainstem, spinal cord and dorsal root ganglion, and in peripheral immune cells such as lymphocytes and monocytes.² The fragment that matters here is α-MSH — alpha-melanocyte-stimulating hormone — the natural template both Melanotan II and bremelanotide were designed from. All melanocortin peptides carry a shared core: "the common amino acid motif HFRW, which is the minimum sequence required for receptor binding and activation".² Hold onto that four-letter motif — His-Phe-Arg-Trp — because you can read it directly out of both synthetic sequences below.

Worth flagging the contrast with a different axis: the hypothalamic–pituitary–gonadal signalling covered in our HPG axis guide is a cascade, where one hormone triggers release of the next in a chain. The melanocortin system is not organised that way — it is one precursor cut into parallel messengers, each going to its own receptor. Different architecture, different logic.

Five receptors, five addresses

Those melanocortin peptides act on five receptors, MC1 through MC5. All five are class A G-protein-coupled receptors, and all five signal primarily through the G_s family — that is, they raise intracellular cyclic AMP by stimulating adenylyl cyclase.¹

What separates them is not the second messenger but where they are and which ligand they prefer. This is the backbone of the whole comparison.

Loci, distributions and endogenous potency orders from the IUPHAR/BPS Guide to PHARMACOLOGY receptor pages;¹ distribution cross-checked against Wang et al. 2019² and Ji et al. 2022.³

Four things fall out of that table that are worth stating plainly.

MC2 is the odd one out. It is the ACTH receptor, and genuinely exclusive — the Guide to PHARMACOLOGY states flatly that "the MC2 receptor only binds ACTH and does not bind the other melanocortin peptides α-, β-, and γ-MSH".¹ It also needs a chaperone: the accessory protein MRAP is required to move the receptor from the endoplasmic reticulum to the cell surface at all.¹ When a compound is called a "non-selective melanocortin agonist", MC2 is almost always excluded from that description by default.

MC1 is the pigmentation receptor. Wang et al. call it "the classical MSH receptor expressed in skin and hair follicles that regulates pigmentation", noting it is also present on immune cells.²

MC3 and MC4 are the central pair. "The neural MCRs, MC3R, and MC4R, are expressed primarily in the CNS and regulate energy homeostasis," per the same review.²

MC5 is the exocrine receptor, and then some. Ji and colleagues describe it as widely distributed and the predominant subtype in skeletal muscle and white adipose tissue.³ MC5R knockout mice are "deficient in the secretion of multiple exocrine glands, including Harderian porphyrin production and lacrimal protein secretion".³ That is the cleanest evidence for the receptor's exocrine role, and it comes from a knockout mouse — a model, not a person.

Structure: one atom apart

Both compounds are cyclic heptapeptides built on the same design idea, which predates either of them by decades.

In 1989, Al-Obeidi, Castrucci, Hadley and Hruby published a set of cyclic lactam analogues of α-melanotropin designed using molecular dynamics.⁴ The strategy was to tie the backbone into a ring by forming an amide (lactam) bond between an acidic side chain — glutamate or aspartate — and a basic one, such as lysine. The point of the constraint is conformational: a linear peptide samples an enormous number of shapes, most of which do not fit a receptor, whereas a cyclised one sits closer to the bound conformation. Their most potent analogue showed "100-fold higher melanotropic potency than α-MSH" in a lizard skin bioassay, and 23- and 24-membered rings showed prolonged residual activity where smaller rings did not.⁴

Melanotan II is that chemistry applied to a shortened α-MSH fragment. Its abbreviated structure is Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂: an acetylated N-terminus, a norleucine at the position corresponding to residue 4 of α-MSH, a lactam bridge between the aspartate side-chain carboxyl and the lysine side-chain amine, and a C-terminal amide. Its molecular formula is C₅₀H₆₉N₁₅O₉.⁵

Bremelanotide is described in the approved US prescribing information as "a synthetic, cyclic heptapeptide with a free acid at the carboxyl terminus and an acetylated amino group at the amino terminus", with the structural formula Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH) and the molecular formula C₅₀H₆₈N₁₄O₁₀, molecular weight 1025.2 as the free base.⁶

Put the two formulas next to each other and the difference is arithmetic:

C₅₀H₆₉N₁₅O₉  −  N  −  H  +  O  →  C₅₀H₆₈N₁₄O₁₀

That is exactly what happens when a C-terminal carboxamide (–CONH₂) is hydrolysed to a free carboxylic acid (–COOH). Every other atom is unchanged: same acetylated N-terminus, same norleucine, same Asp–Lys lactam bridge, same core residues.

Those core residues are where the POMC ancestry becomes visible. Read the middle of either sequence — His-D-Phe-Arg-Trp — and you are looking at the HFRW motif Wang et al. identify as the minimum sequence for melanocortin receptor binding and activation,² with the L-phenylalanine swapped for its D-enantiomer. That stereochemical inversion is a classic medicinal-chemistry move: D-amino acids resist the proteases that chew through natural L-peptides.

Selectivity: what the numbers say

The usual one-line summary of this pair is that Melanotan II is non-selective and PT-141 is MC4R-selective. That is close enough to be useful and wrong enough to be worth correcting. Start with the binding data: the IUPHAR/BPS Guide to PHARMACOLOGY lists affinities for both compounds across four of the five receptors.¹

Values as listed in the IUPHAR/BPS Guide to PHARMACOLOGY, human receptors.¹ Note that MT-II figures at MC1 and MC5 are pIC₅₀ values and the remainder are pK_i — different measurements from different assays. Read down a column with confidence; read across a row with caution.

Reading down the Melanotan II column, the profile is genuinely flat — roughly one order of magnitude separates its strongest and weakest listed value across four receptors. That is what "non-selective" means in practice: not that a compound hits everything identically, but that no single receptor stands out far enough to dominate the pharmacology.

The bremelanotide column has a clear peak. MC4 at pK_i 9.6 sits about 25-fold above MC1 at 8.2, roughly 60-fold above MC5 and around 200-fold above MC3. So bremelanotide is MC4-preferring in binding, by a margin that would matter in most assay designs.

Now the complication, and it is a real one. The approved US label states that bremelanotide "is a melanocortin receptor (MCR) agonist that nonselectively activates several receptor subtypes with the following order of potency: MC1R, MC4R, MC3R, MC5R, MC2R", noting that of these, binding at MC1R and MC4R is most relevant.⁶

That puts MC1R first, ahead of MC4R — the opposite order from the binding table. Both can be correct, because they measure different things. Binding affinity (K_i) describes how tightly a ligand occupies a receptor; functional potency (EC₅₀) describes how much ligand is needed to produce a signalling response, folding in receptor reserve, coupling efficiency and assay background. A compound can bind receptor A more tightly while activating receptor B at lower concentrations.

The honest formulation, then: bremelanotide is a melanocortin agonist with a binding profile weighted toward MC4, but it is not an MC4-selective compound, and no regulatory or pharmacological source we retrieved describes it as one. "More MC4-weighted than Melanotan II" is defensible. "MC4-selective" is not.

Side by side

The relationship between the two rows is the interesting part. Because the only difference is a C-terminal amide versus a free acid, and because hydrolysis of a carboxamide is an ordinary metabolic transformation, bremelanotide is commonly described as a deamidated metabolite of Melanotan II. The structural claim is solid — two independent authoritative sources give formulas differing by exactly −NH +O.^5,6 The metabolic claim is a well-supported inference, but we could not retrieve a primary study demonstrating that conversion in a biological matrix, so we will not state it as established fact.

Two very different regulatory histories

This section is a factual account of what regulators have said and done. It is not advice, and it says nothing about whether either compound is suitable for anything.

Bremelanotide went through conventional pharmaceutical development. A bremelanotide injection product was reviewed by the US Food and Drug Administration under new drug application 210557; the FDA's multidiscipline review describes the substance as "a synthetic heptapeptide and melanocortin receptor (MCR) agonist".⁹ The approved prescribing information records an initial US approval date of 2019 for a specific named indication in premenopausal women.⁶ We do not describe that indication here — this guide is about receptor pharmacology, and the material Patriot Labs supplies is a research chemical, not that product.

Melanotan II did not follow that path, and has instead been the subject of published statements from national medicines regulators. Australia's Therapeutic Goods Administration states that melanotan products are not approved for supply in Australia and characterises Melanotan II as an unlawful therapeutic good under the Therapeutic Goods Act 1989; the same notice records an individual in New South Wales receiving 27 infringement notices totalling $101,412 in connection with alleged supply of Melanotan II to Australian consumers.⁷ In the United Kingdom, a written parliamentary answer from the Department of Health and Social Care dated 16 June 2014 states: "No Melanotan product holds a marketing authorisation (product licence) for use in the UK and consequently advertising and sale or supply would be in breach of regulatory requirements."⁸ Comparable advisories have been issued over the years by agencies in Denmark, Ireland and Norway.¹⁰

The distinction to take from this is narrow and important: the gap in regulatory standing is a fact about dossiers submitted to agencies, not a ranking of the molecules. Bremelanotide has one. Melanotan II does not. Neither observation tells you anything about how either behaves in an assay, and neither makes any research-grade material fit for use in a person.

What the evidence does not establish

Everything above is drawn from receptor databases, a regulatory dossier and review literature. Here is what that body of evidence does not support.

It does not establish clean receptor selectivity for either compound. Both are best described as broad melanocortin agonists. Bremelanotide's binding is weighted toward MC4, but the approved label explicitly calls the compound non-selective and ranks MC1R first on functional potency.⁶ Any design that assumes single-receptor action for either peptide is assuming something the published data do not support.

The affinity numbers are not interchangeable. The values in the selectivity table come from different laboratories using different assays — some radioligand displacement against [¹²⁵I]NDP-α-MSH, some functional. pIC₅₀ and pK_i are not the same quantity, and IC₅₀ depends on the radioligand concentration used. Comparing a compound against itself across receptors within one dataset is reasonably safe. Comparing two compounds at one receptor across datasets is not.

Species differences are real and documented here specifically. Human MC1R is described as "supersensitive" to melanocortin peptides relative to the mouse receptor.¹ Anything transferred from a rodent model to a human receptor system in this family carries a known translation risk.

The metabolite relationship is inferred, not demonstrated. The structures differ by exactly the atoms you would lose in a deamidation, which is a strong argument. It is not the same as a published pharmacokinetic study identifying bremelanotide as a circulating metabolite of Melanotan II. We did not retrieve one.

MC5R's exocrine role rests substantially on knockout mice. The secretory deficits described — Harderian porphyrin, lacrimal protein — are mouse phenotypes,³ and mice have exocrine structures humans do not. Useful mechanistic evidence about the receptor; not a claim about anything else.

Nothing above describes an effect in a person. Deliberately. Receptor affinity is a property of a molecule and a protein in a defined assay system, several inferential steps away from any organism-level statement. This guide does not take those steps.

Why any of this matters at the bench

Selectivity data is not trivia; it constrains how a melanocortin experiment can be interpreted.

If a preparation expresses more than one melanocortin receptor — and given the distributions in the first table, many primary cells and tissues do — a response to either peptide cannot be attributed to a single receptor without further work. Skin is the obvious case: MC1 sits on melanocytes, MC5 and MC2 are both listed in skin, and MC4 appears on dermal papilla cells.^1,2 A cAMP readout from a skin-derived culture given a non-selective melanocortin agonist tells you the system responded, not which receptor carried the signal. The usual ways to close that gap are receptor-selective antagonists, knockdown or knockout lines, or transfected single-receptor backgrounds — which is why so much of the affinity data in the Guide to PHARMACOLOGY is generated in cells expressing one human receptor at a time.¹ Endogenous antagonists matter too: agouti and AGRP act as high-affinity inverse agonists at specific melanocortin receptors,¹ so baseline melanocortin tone is set by more than agonist availability.

One identity note follows from the chemistry rather than from any usage guidance. The amide-versus-acid distinction between these two molecules is exactly what a mass-spec identity check resolves and a purity-only HPLC number does not, since the two species differ by roughly one mass unit in a molecule of over a thousand. To confirm which of the two a vial actually contains, read the mass spectrometry section of the certificate of analysis — see reading a peptide COA.

Frequently asked questions

Is PT-141 really a metabolite of Melanotan II? The two differ by a single functional group — Melanotan II carries a C-terminal amide, bremelanotide a free acid — and the published formulas differ by exactly −N, −H, +O, which is what deamidation produces.^5,6 Hydrolysis of a C-terminal amide is a routine metabolic step, so the description is well founded. We could not retrieve a primary metabolism study demonstrating the conversion, so we treat the structure as fact and the metabolic route as a strong inference.

Which melanocortin receptors does each peptide bind? Both are broad agonists. Melanotan II is listed with high affinity at MC1, MC3, MC4 and MC5 with little separation between them; bremelanotide's highest listed affinity is at MC4 (pK_i 9.6), roughly 25-fold above MC1 (pK_i 8.2).¹ Neither engages MC2, which recognises only ACTH.¹

Why does the FDA label call bremelanotide non-selective if the binding data favour MC4? Affinity and functional potency are different measurements. The label gives a potency order of MC1R, MC4R, MC3R, MC5R, MC2R;⁶ the binding database ranks MC4 first.¹ A ligand can bind one receptor more tightly while activating another at lower concentrations.

What is POMC and why does it keep coming up? Proopiomelanocortin is a single precursor protein that prohormone convertases cut into separate signalling peptides — ACTH, the MSHs, β-endorphin and others, eleven products in the Guide to PHARMACOLOGY's count.¹ α-MSH, the template for both peptides here, is one of them, which is why both retain the His-Phe-Arg-Trp core motif.²

Do the two compounds have the same regulatory history? No, and it is the sharpest difference between them. Bremelanotide completed a formal development programme and a bremelanotide product received initial US approval in 2019.^6,9 Melanotan II has no marketing authorisation; Australia's TGA has published enforcement action against its supply,⁷ and the UK Department of Health has stated that no melanotan product holds a UK product licence.⁸

Is either compound approved for human use? No. The material described here is sold strictly for in-vitro research and laboratory use only and is not for human or veterinary consumption. The existence of an approved pharmaceutical product containing bremelanotide is irrelevant to research-grade material, a different article made, released and supplied under entirely different conditions.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.